Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
Domainzf-C2H2

ZNF467 ADNP ZNF10 ZNF132 ZNF134 ZNF707

1.50e-04693236PF00096
DomainZnf_C2H2/integrase_DNA-bd

ZNF467 ADNP ZNF10 ZNF132 ZNF134 ZNF707

1.51e-04694236IPR013087
DomainZINC_FINGER_C2H2_2

ZNF467 ADNP ZNF10 ZNF132 ZNF134 ZNF707

2.76e-04775236PS50157
DomainZINC_FINGER_C2H2_1

ZNF467 ADNP ZNF10 ZNF132 ZNF134 ZNF707

2.79e-04777236PS00028
DomainZnf_C2H2-like

ZNF467 ADNP ZNF10 ZNF132 ZNF134 ZNF707

3.18e-04796236IPR015880
DomainZnf_C2H2

ZNF467 ADNP ZNF10 ZNF132 ZNF134 ZNF707

3.38e-04805236IPR007087
DomainZnF_C2H2

ZNF467 ADNP ZNF10 ZNF132 ZNF134 ZNF707

3.45e-04808236SM00355
Domain-

ZNF467 ZNF10 ZNF132 ZNF134 ZNF707

1.22e-036792353.30.160.60
Domain-

LGALS7 CNTNAP2

6.04e-03952322.60.120.200
DomainKRAB

ZNF10 ZNF132 ZNF707

9.31e-03358233PS50805
DomainKRAB

ZNF10 ZNF132 ZNF707

9.31e-03358233PF01352
DomainKRAB

ZNF10 ZNF132 ZNF707

1.01e-02369233SM00349
DomainKRAB

ZNF10 ZNF132 ZNF707

1.02e-02370233IPR001909
Pubmed

CHD3 and CHD4 form distinct NuRD complexes with different yet overlapping functionality.

ADNP GTPBP4 RPL10 LGALS7 NOC3L

5.06e-0560524528977666
Pubmed

Isolation and fine mapping of 16 novel human zinc finger-encoding cDNAs identify putative candidate genes for developmental and malignant disorders.

ZNF132 ZNF134

6.17e-05172427557990
Pubmed

The cell proliferation antigen Ki-67 organises heterochromatin.

WDR76 GTPBP4 RPL10 NOC3L

1.68e-0441024426949251
Pubmed

DEAD-box helicase DDX27 regulates 3' end formation of ribosomal 47S RNA and stably associates with the PeBoW-complex.

GTPBP4 NOC3L

3.33e-043924225825154
Pubmed

MYC multimers shield stalled replication forks from RNA polymerase.

ADNP GTPBP4 RPL10 LGALS7 NOC3L

4.99e-0498924536424410
Pubmed

Identification of SH3 domain interaction partners of human FasL (CD178) by phage display screening.

DOCK4 NCKIPSD

5.48e-045024219807924
Pubmed

Identification of proteins associated with ligand-activated estrogen receptor α in human breast cancer cell nuclei by tandem affinity purification and nano LC-MS/MS.

GTPBP4 RPL10 LGALS7

6.26e-0424524321182205
InteractionEBNA1BP2 interactions

ZNF467 ADNP GTPBP4 RPL10 NOC3L

1.72e-05324215int:EBNA1BP2
Cytoband19q13.4

ZNF132 ZNF134

7.87e-047924219q13.4
GeneFamilyZinc fingers C2H2-type|ZF class homeoboxes and pseudogenes

ZNF467 ZNF10 ZNF132 ZNF134 ZNF707

2.95e-0471816528
DrugSulfamethoxypyridazine [80-35-3]; Down 200; 14.2uM; MCF7; HT_HG-U133A

WDR76 ZNF467 EPOR ZNF134 POFUT1 NCKIPSD

3.27e-081952363409_DN
DrugDemeclocycline hydrochloride [64-73-3]; Down 200; 8uM; MCF7; HT_HG-U133A

B4GALT2 WDR76 EPOR ZNF134 POFUT1 NCKIPSD

3.47e-081972363404_DN
DrugChlorhexidine [55-56-1]; Down 200; 8uM; MCF7; HT_HG-U133A

ZNF10 EPOR POFUT1 RPL10 NCKIPSD

1.47e-062002355403_DN
DrugHarpagoside [19210-12-9]; Down 200; 8uM; MCF7; HT_HG-U133A

WDR76 GTPBP4 POFUT1 RPL10

3.75e-051912344981_DN
DrugDanazol [17230-88-5]; Down 200; 11.8uM; PC3; HG-U133A

B4GALT2 EPOR RPL10 NCKIPSD

3.99e-051942341954_DN
DrugNabumetone [42924-53-8]; Down 200; 17.6uM; MCF7; HT_HG-U133A

WDR76 ZNF10 EPOR POFUT1

4.07e-051952345428_DN
DrugTiapride hydrochloride [51012-33-0]; Down 200; 11uM; MCF7; HT_HG-U133A

WDR76 GTPBP4 ZNF134 POFUT1

4.07e-051952344686_DN
DrugMethylhydantoin-5-(L) [40856-73-3]; Down 200; 35uM; MCF7; HT_HG-U133A

B4GALT2 WDR76 ZNF10 POFUT1

4.15e-051962345679_DN
DrugICI182,780; Up 200; 1uM; MCF7; HT_HG-U133A

ZNF467 ZNF10 EPOR POFUT1

4.15e-051962347091_UP
DrugFluspirilen [1841-19-6]; Down 200; 8.4uM; HL60; HT_HG-U133A

GTPBP4 EPOR ZNF134 POFUT1

4.15e-051962343086_DN
DrugUrapidil hydrochloride [64887-14-5]; Down 200; 9.4uM; MCF7; HT_HG-U133A

B4GALT2 WDR76 ZNF467 EPOR

4.23e-051972346455_DN
DrugMethylprednisolone, 6-alpha [83-43-2]; Down 200; 10.6uM; MCF7; HT_HG-U133A

WDR76 ZNF467 EPOR POFUT1

4.23e-051972346785_DN
DrugPirenzepine dihydrochloride [29868-97-1]; Down 200; 9.4uM; PC3; HT_HG-U133A

ZNF10 EPOR POFUT1 CNTNAP2

4.23e-051972345872_DN
DrugDinoprost trometamol [38362-01-5]; Down 200; 8.4uM; MCF7; HT_HG-U133A

ZNF467 GTPBP4 EPOR ZNF134

4.23e-051972343308_DN
DrugAmitryptiline hydrochloride [549-18-8]; Down 200; 12.8uM; MCF7; HT_HG-U133A

WDR76 GTPBP4 EPOR POFUT1

4.32e-051982341701_DN
DrugRolipram [61413-54-5]; Down 200; 14.6uM; PC3; HT_HG-U133A

ZNF467 ZNF10 EPOR CNTNAP2

4.32e-051982346730_DN
DrugNafronyl oxalate [3200-06-4]; Down 200; 8.4uM; PC3; HT_HG-U133A

ZNF467 ZNF10 ORAI3 CNTNAP2

4.32e-051982346687_DN
DrugTrolox [53188-07-1]; Down 200; 16uM; MCF7; HT_HG-U133A

B4GALT2 WDR76 EPOR POFUT1

4.40e-051992342883_DN
DrugSer-Gly

EPOR LGALS7

1.32e-0417232CID000136488
DrugGly-L-Ser

EPOR LGALS7

1.83e-0420232CID000073086
DrugDFDNB

EPOR LGALS7

4.17e-0430232CID000067598
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A

ZNF467 ADNP POFUT1

6.27e-041682333395_DN
Drugtrichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A

ZNF467 ADNP RPL10

6.49e-041702337043_DN
DrugTrichostatin A, Streptomyces sp.; Up 200; 1uM; MCF7; HT_HG-U133A_EA

ZNF10 DOCK4 EPOR

6.49e-041702331014_UP
DrugTrichostatin A, from Streptomyces sp.; Up 200; 0.1uM; MCF7; HT_HG-U133A

ZNF10 DOCK4 EPOR

7.06e-041752332777_UP
DrugTrichostatin A, Streptomyces sp.; Up 200; 0.1uM; MCF7; HT_HG-U133A_EA

ZNF10 DOCK4 EPOR

7.18e-04176233992_UP
DrugTrichostatin A, from Streptomyces sp.; Up 200; 0.1uM; MCF7; HT_HG-U133A

ZNF10 DOCK4 EPOR

7.30e-041772336784_UP
DrugTrichostatin A, from Streptomyces sp.; Up 200; 0.1uM; MCF7; HT_HG-U133A

ZNF10 DOCK4 EPOR

7.30e-041772336493_UP
DrugTrichostatin A, from Streptomyces sp.; Up 200; 0.1uM; MCF7; HT_HG-U133A

ZNF10 DOCK4 EPOR

7.30e-041772333312_UP
DrugTrichostatin A, from Streptomyces sp.; Up 200; 0.1uM; MCF7; HT_HG-U133A

ZNF10 DOCK4 EPOR

7.66e-041802335484_UP
DrugTrichostatin A, from Streptomyces sp.; Up 200; 0.1uM; MCF7; HT_HG-U133A

ZNF10 DOCK4 EPOR

7.66e-041802332247_UP
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A

ZNF467 ADNP RPL10

7.78e-041812337005_DN
DrugMycophenolic acid [24280-93-1]; Up 200; 12.4uM; MCF7; HT_HG-U133A

WDR76 ORAI3 EPOR

7.78e-041812332857_UP
DrugRescinnamin [24815-24-5]; Up 200; 6.4uM; MCF7; HT_HG-U133A

EPOR CMKLR2 POFUT1

7.78e-041812332785_UP
Drugtrichostatin A, Streptomyces sp.; Up 200; 1uM; MCF7; HT_HG-U133A

ZNF10 DOCK4 EPOR

7.91e-041822337043_UP
DrugMefloquine hydrochloride [51773-92-3]; Up 200; 9.6uM; MCF7; HT_HG-U133A

DOCK4 ORAI3 POFUT1

7.91e-041822336205_UP
Drugtrichostatin A, Streptomyces sp.; Up 200; 1uM; MCF7; HT_HG-U133A

ZNF10 DOCK4 EPOR

8.04e-041832336434_UP
DrugLY 294002; Up 200; 10uM; MCF7; HT_HG-U133A

ZNF10 ORAI3 POFUT1

8.04e-041832335599_UP
Drug17-AAG; Up 200; 1uM; MCF7; HT_HG-U133A

EPOR ZNF134 RPL10

8.04e-041832336985_UP
DrugMS-275; Up 200; 10uM; PC3; HT_HG-U133A

DOCK4 EPOR CNTNAP2

8.04e-041832337084_UP
DrugCP-690334-01 [459212-38-5]; Up 200; 10uM; MCF7; HT_HG-U133A

ZNF10 EPOR CNTNAP2

8.42e-041862334380_UP
Drug17-AAG; Down 200; 1uM; PC3; HT_HG-U133A

ZNF467 RPL10 CNTNAP2

8.69e-041882335958_DN
Drugforskolin; Down 200; 50uM; MCF7; HT_HG-U133A_EA

WDR76 GTPBP4 POFUT1

8.82e-04189233913_DN
Drug17-AAG; Down 200; 1uM; MCF7; HT_HG-U133A

WDR76 GTPBP4 POFUT1

8.82e-041892335578_DN
DrugAmpyrone [83-07-8]; Down 200; 19.6uM; PC3; HT_HG-U133A

WDR76 ZNF10 CNTNAP2

8.96e-041902334507_DN
DrugRoxithromycin [80214-83-1]; Down 200; 4.8uM; MCF7; HT_HG-U133A

EPOR POFUT1 RPL10

8.96e-041902333331_DN
DrugAntimycin A [1397-94-0]; Down 200; 7.2uM; MCF7; HT_HG-U133A

WDR76 DOCK4 RPL10

9.09e-041912332261_DN
DrugDimethisoquin hydrochloride [2773-92-4]; Up 200; 13uM; MCF7; HT_HG-U133A

EPOR CMKLR2 POFUT1

9.09e-041912334791_UP
DrugPiribedil hydrochloride [78213-63-5]; Down 200; 12uM; MCF7; HT_HG-U133A

ZNF10 RPL10 CNTNAP2

9.09e-041912335434_DN
DrugRapamycin; Up 200; 0.1uM; MCF7; HT_HG-U133A_EA

ORAI3 EPOR POFUT1

9.09e-041912331080_UP
DrugThioperamide maleate [106243-16-7]; Up 200; 9.8uM; MCF7; HT_HG-U133A

EPOR CMKLR2 POFUT1

9.09e-041912333392_UP
Drugrottlerin; Down 200; 10uM; MCF7; HT_HG-U133A_EA

WDR76 GTPBP4 POFUT1

9.09e-04191233941_DN
DrugAntipyrine, 4-hydroxy [1672-63-5]; Up 200; 19.6uM; MCF7; HT_HG-U133A

CMKLR2 POFUT1 CNTNAP2

9.23e-041922334175_UP
DrugErgocryptine-alpha [511-09-1]; Up 200; 7uM; HL60; HT_HG-U133A

ZNF467 ZNF10 DOCK4

9.23e-041922332572_UP
DrugRapamycin; Up 200; 0.1uM; MCF7; HT_HG-U133A_EA

ORAI3 EPOR POFUT1

9.23e-041922331059_UP
DrugAG-013608 [351320-38-2]; Down 200; 10uM; MCF7; HT_HG-U133A

WDR76 POFUT1 RPL10

9.23e-041922336435_DN
DrugFillalbin [4540-25-4]; Up 200; 13.8uM; MCF7; HT_HG-U133A

CMKLR2 POFUT1 RPL10

9.23e-041922332813_UP
DrugNimodipine [66085-59-4]; Down 200; 9.6uM; HL60; HT_HG-U133A

WDR76 ZNF10 NCKIPSD

9.37e-041932333103_DN
DrugNefopam hydrochloride [23327-57-3]; Down 200; 13.8uM; MCF7; HT_HG-U133A

WDR76 EPOR POFUT1

9.37e-041932333627_DN
DrugPF-00539758-00 [351321-34-1]; Up 200; 10uM; PC3; HT_HG-U133A

ZNF10 RPL10 CNTNAP2

9.37e-041932336421_UP
DrugCephalosporanic acid, 7-amino [957-68-6]; Down 200; 14.6uM; MCF7; HT_HG-U133A

WDR76 GTPBP4 EPOR

9.37e-041932333258_DN
DrugNorfloxacin [70458-96-7]; Down 200; 12.6uM; MCF7; HT_HG-U133A

WDR76 POFUT1 CNTNAP2

9.37e-041932335985_DN
DrugHaloperidol [52-86-8]; Down 200; 10.6uM; MCF7; HT_HG-U133A

CMKLR2 ZNF134 POFUT1

9.37e-041932335273_DN
DrugDosulepin hydrochloride [897-15-4]; Down 200; 12uM; MCF7; HT_HG-U133A

GTPBP4 POFUT1 CNTNAP2

9.37e-041932335986_DN
DrugImipramine hydrochloride [113-52-0]; Down 200; 12.6uM; MCF7; HT_HG-U133A

POFUT1 RPL10 CNTNAP2

9.37e-041932335440_DN
Drugtroglitazone; Up 200; 10uM; MCF7; HT_HG-U133A

ZNF10 EPOR POFUT1

9.51e-041942335229_UP
DrugHydroxytacrine maleate (R,S) [118909-22-1]; Down 200; 12.2uM; HL60; HT_HG-U133A

DOCK4 GTPBP4 POFUT1

9.51e-041942332430_DN
DrugKainic Acid

B4GALT2 ADNP EPOR

9.51e-04194233ctd:D007608
DrugRapamycin; Down 200; 0.1uM; PC3; HT_HG-U133A

GTPBP4 NCKIPSD NOC3L

9.51e-041942331221_DN
Drug0173570-0000 [211245-44-2]; Down 200; 1uM; MCF7; HT_HG-U133A

ZNF134 RPL10 NCKIPSD

9.51e-041942334715_DN
DrugSpiramycin [8025-81-8]; Down 200; 4.8uM; MCF7; HT_HG-U133A

B4GALT2 WDR76 EPOR

9.51e-041942333419_DN
DrugPropantheline bromide [50-34-0]; Up 200; 9uM; MCF7; HT_HG-U133A

EPOR CMKLR2 POFUT1

9.51e-041942334798_UP
DrugCyclizine hydrochloride [303-25-3]; Up 200; 13.2uM; MCF7; HT_HG-U133A

EPOR POFUT1 CNTNAP2

9.51e-041942335525_UP
DrugRapamycin; Down 200; 0.1uM; MCF7; HT_HG-U133A

B4GALT2 ZNF467 ZNF134

9.51e-041942337001_DN
Drug(R) -Naproxen sodium salt [26159-34-2]; Down 200; 15.8uM; MCF7; HT_HG-U133A

WDR76 ZNF467 EPOR

9.51e-041942336794_DN
DrugNaproxen [22204-53-1]; Down 200; 17.4uM; MCF7; HT_HG-U133A

EPOR RPL10 CNTNAP2

9.51e-041942335457_DN
DrugGriseofulvin [126-07-8]; Down 200; 11.2uM; MCF7; HT_HG-U133A

EPOR ZNF134 POFUT1

9.51e-041942332293_DN
DrugMethoxy-6-harmalan [3589-73-9]; Down 200; 18.6uM; MCF7; HT_HG-U133A

EPOR RPL10 NCKIPSD

9.66e-041952335455_DN
DrugDinoprost trometamol [38362-01-5]; Down 200; 8.4uM; HL60; HT_HG-U133A

ZNF134 POFUT1 NOC3L

9.66e-041952332446_DN
DrugAminopurine, 6-benzyl [1214-39-7]; Down 200; 17.8uM; MCF7; HT_HG-U133A

WDR76 EPOR POFUT1

9.66e-041952334748_DN
DrugEsculin Hydrate [531-75-9]; Down 200; 11.8uM; PC3; HT_HG-U133A

ORAI3 NCKIPSD CNTNAP2

9.66e-041952336310_DN
DrugAminopurine, 6-benzyl [1214-39-7]; Down 200; 17.8uM; MCF7; HT_HG-U133A

ZNF10 EPOR POFUT1

9.66e-041952332313_DN
DrugSalsolinol hydrobromide [38221-21-5]; Down 200; 15.4uM; MCF7; HT_HG-U133A

WDR76 GTPBP4 EPOR

9.66e-041952332791_DN
Drugwortmannin from Penicillium funiculosum; Down 200; 0.01uM; PC3; HT_HG-U133A

GTPBP4 ZNF134 NOC3L

9.66e-041952331243_DN
DrugZomepirac sodium salt [64092-48-4]; Up 200; 12.8uM; MCF7; HT_HG-U133A

B4GALT2 WDR76 POFUT1

9.66e-041952333454_UP
DrugIsradipine [75695-93-1]; Down 200; 10.8uM; MCF7; HT_HG-U133A

ZNF10 POFUT1 RPL10

9.66e-041952335447_DN
DrugEthionamide [536-33-4]; Up 200; 24uM; PC3; HT_HG-U133A

CMKLR2 POFUT1 CNTNAP2

9.66e-041952334593_UP
DrugDicumarol [66-76-2]; Up 200; 11.8uM; MCF7; HT_HG-U133A

B4GALT2 EPOR CNTNAP2

9.66e-041952333423_UP
DrugNafcillin sodium salt monohydrate [7177-50-6]; Down 200; 8.8uM; MCF7; HT_HG-U133A

WDR76 GTPBP4 ZNF134

9.66e-041952333323_DN
DrugFluorometholone [426-13-1]; Up 200; 10.6uM; MCF7; HT_HG-U133A

EPOR CMKLR2 CNTNAP2

9.66e-041952336071_UP
DrugDeoxycorticosterone [64-85-7]; Up 200; 12.2uM; HL60; HT_HG-U133A

CMKLR2 RPL10 CNTNAP2

9.66e-041952333099_UP
DrugMyosmine [532-12-7]; Up 200; 27.4uM; MCF7; HT_HG-U133A

ORAI3 CMKLR2 CNTNAP2

9.66e-041952333634_UP
DrugIodixanol [92339-11-2]; Up 200; 2.6uM; MCF7; HT_HG-U133A

B4GALT2 WDR76 CMKLR2

9.66e-041952334848_UP
DrugNaringin hydrate [11032-30-7]; Down 200; 6.6uM; MCF7; HT_HG-U133A

EPOR ZNF134 POFUT1

9.66e-041952333286_DN
Drug3-Acetylcoumarin [3949-36-8]; Down 200; 21.2uM; PC3; HT_HG-U133A

ZNF467 CMKLR2 CNTNAP2

9.66e-041952334664_DN
DrugPrednicarbate [73771-04-7]; Up 200; 8.2uM; MCF7; HT_HG-U133A

DOCK4 POFUT1 RPL10

9.66e-041952333542_UP
DrugMethacholine chloride [62-51-1]; Up 200; 20.4uM; MCF7; HT_HG-U133A

ZNF10 EPOR NCKIPSD

9.66e-041952333452_UP
DrugCloxacillin sodium salt [642-78-4]; Up 200; 8.8uM; PC3; HT_HG-U133A

ZNF467 POFUT1 CNTNAP2

9.66e-041952332126_UP
DrugProbucol [23288-49-5]; Down 200; 7.8uM; MCF7; HT_HG-U133A

EPOR ZNF134 RPL10

9.66e-041952335626_DN
DrugPirenperone [ 75444-65-4]; Down 200; 10.2uM; MCF7; HT_HG-U133A

ZNF10 DOCK4 CMKLR2

9.80e-041962335639_DN
DiseaseAutistic Disorder

ADNP DOCK4 RPL10 CNTNAP2

4.64e-05261234C0004352
Diseaseautistic disorder (is_implicated_in)

RPL10 CNTNAP2

4.91e-0442232DOID:12849 (is_implicated_in)
Diseasecommon carotid intimal medial thickness

NOC3L CNTNAP2

1.25e-0367232EFO_0004860
Diseasestem Cell Growth Factor beta measurement

CFAP61 CNTNAP2

1.56e-0375232EFO_0008292
Diseaselongitudinal BMI measurement

DOCK4 CNTNAP2

1.86e-0382232EFO_0005937
Diseasecomplement factor D measurement

RTTN CNTNAP2

2.38e-0393232EFO_0020283

Protein segments in the cluster

PeptideGeneStartEntry
HHLRERHQVIQTVHP

ADNP

641

Q9H2P0
AVIIPFRHREHHLRY

B4GALT2

146

O60909
RHSHYPQLHVRKARV

CFAP61

176

Q8NHU2
ERILHNVHLYHIVQR

ABCD2

581

Q9UBJ2
PTVIHKHYQIHRIRH

GTPBP4

31

Q9BZE4
HQSPHQRLHRYVELA

ORAI3

136

Q9BRQ5
QYHHFRHRLPLARVR

LGALS7

106

P47929
SRYILLPVVLHHLHI

DOCK4

826

Q8N1I0
RHRYRHPSTLQLPHL

ITIH6

1211

Q6UXX5
PRYHRVIHINEVVLL

EPOR

131

P19235
VRHELQHPIIARYVR

CNTNAP2

146

Q9UHC6
LRRHYHPIVQRFAAH

NOC3L

696

Q8WTT2
IHAHLVRPYVGIHLR

POFUT1

226

Q9H488
VPHHVHVLLAILYRL

OR52L2P

286

Q8NGH6
SVFRRYHLPVHVIGH

RTTN

981

Q86VV8
HIRVRLHPFHVIRIN

RPL10

86

P27635
AIVRTTPYLQHRHRL

NCKIPSD

666

Q9NZQ3
YIHLIHPVLSHRHRT

CMKLR2

136

P46091
RLAQHRKVHTEHRPY

ZNF707

246

Q96C28
HLVRHQRVHTQERPY

ZNF132

641

P52740
HLILHQRTHVRVRPY

ZNF10

391

P21506
IRTVHVHPVHRQYFI

WDR76

451

Q9H967
HLVRHQRVHTGERPY

ZNF134

386

P52741
HLIRHQRIHTGERPY

ZNF467

286

Q7Z7K2